Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017
We would like to express our opinion regarding a Parise and Caggiano paper recently published in your journal. We certainly believe this is a great contribution, since it found that node-negative HER2 (+) breast cancer patients have better survival contrary to the common knowledge. This finding coul...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2018-04, Vol.168 (2), p.577-578 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 578 |
|---|---|
| container_issue | 2 |
| container_start_page | 577 |
| container_title | Breast cancer research and treatment |
| container_volume | 168 |
| creator | Pichilingue-Febres, Alejandra F. Arias-Linares, Miguel A. Araujo-Castillo, Roger V. |
| description | We would like to express our opinion regarding a Parise and Caggiano paper recently published in your journal. We certainly believe this is a great contribution, since it found that node-negative HER2 (+) breast cancer patients have better survival contrary to the common knowledge. This finding could reflect the consequences of targeted therapies that are changing the natural history of the disease. However, we think that such an interesting analysis could also have been done with stage III and IV patients, since this group of people could benefit greatly from these findings. In fact, new guidelines now recommend the use of HER2-specific therapy for stage IV patients with positive markers, even for life if they do not show signs of progression. Additionally, we would like to discuss the value of adding the Ki-67 marker to the classification proposed by the authors, because several papers consider it an important prognostic factor. |
| doi_str_mv | 10.1007/s10549-017-4620-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1979968041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A530007770</galeid><sourcerecordid>A530007770</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-cbdf5d30da0600f1645b55366af2b2b55686e3dd291f65a4650fc030361b0b4c3</originalsourceid><addsrcrecordid>eNp1ksFu1DAQhiMEotvCA3BBlpBQD5vu2Ens5rhEC0WqRBUFrpaTOFuXxF5sBym3Pgg8AW_VJ8HbFGgRyAfbM9__yzOeKHqB4QQDsJXDkKV5DJjFKSUQT4-iBc5YEjOC2eNoAZiymJ4CPYgOnbsCgJxB_jQ6IDlhQPN8Ef0ozDBI7R0yGt1cfyuV-4xMhwZjveiVn_YXbVoZa7kVXn2VS7QpVxfl6mxTElRbKZxHjdCNtMiNtZ920iGlUYWXqCJLJHSLqgT5MTi6m-vvqJ7QhbDKSVSsb7OF2G6V0AZ9WqI3s18x-5XBqgoRv0QkFPksetKJ3snnd_tR9PHtpirO4vMP794X6_O4yXDi46Zuu6xNoBVAATpM06zOsoRS0ZGahCM9pTJpW5LjjmYipRl0DSSQUFxDnTbJUXQ8--6s-TJK5_mgXCP7XmhpRsdxzvI8tDXFAX31F3plRqvD624pxgJJ_lBb0UuudGe8Fc3elK-zJHxL4CBQJ_-gwmrloBqjZadC_IHg9T3BpRS9v3SmH70y2j0E8Qw21jhnZcd3Vg3CThwD308SnyeJhybz_STxKWhe3lU21oNsfyt-jU4AyAy4kNJbae-V_l_XnwtDz6M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1979777992</pqid></control><display><type>article</type><title>Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Pichilingue-Febres, Alejandra F. ; Arias-Linares, Miguel A. ; Araujo-Castillo, Roger V.</creator><creatorcontrib>Pichilingue-Febres, Alejandra F. ; Arias-Linares, Miguel A. ; Araujo-Castillo, Roger V.</creatorcontrib><description>We would like to express our opinion regarding a Parise and Caggiano paper recently published in your journal. We certainly believe this is a great contribution, since it found that node-negative HER2 (+) breast cancer patients have better survival contrary to the common knowledge. This finding could reflect the consequences of targeted therapies that are changing the natural history of the disease. However, we think that such an interesting analysis could also have been done with stage III and IV patients, since this group of people could benefit greatly from these findings. In fact, new guidelines now recommend the use of HER2-specific therapy for stage IV patients with positive markers, even for life if they do not show signs of progression. Additionally, we would like to discuss the value of adding the Ki-67 marker to the classification proposed by the authors, because several papers consider it an important prognostic factor.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-017-4620-y</identifier><identifier>PMID: 29270699</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomarkers, Tumor ; Breast cancer ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; ErbB-2 protein ; Female ; Health aspects ; Humans ; Letter to the Editor ; Medicine ; Medicine & Public Health ; Neoplasm Staging ; Oncology ; Prognosis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Tumors</subject><ispartof>Breast cancer research and treatment, 2018-04, Vol.168 (2), p.577-578</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2017</rights><rights>COPYRIGHT 2018 Springer</rights><rights>Breast Cancer Research and Treatment is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-cbdf5d30da0600f1645b55366af2b2b55686e3dd291f65a4650fc030361b0b4c3</citedby><cites>FETCH-LOGICAL-c513t-cbdf5d30da0600f1645b55366af2b2b55686e3dd291f65a4650fc030361b0b4c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-017-4620-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-017-4620-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29270699$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pichilingue-Febres, Alejandra F.</creatorcontrib><creatorcontrib>Arias-Linares, Miguel A.</creatorcontrib><creatorcontrib>Araujo-Castillo, Roger V.</creatorcontrib><title>Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>We would like to express our opinion regarding a Parise and Caggiano paper recently published in your journal. We certainly believe this is a great contribution, since it found that node-negative HER2 (+) breast cancer patients have better survival contrary to the common knowledge. This finding could reflect the consequences of targeted therapies that are changing the natural history of the disease. However, we think that such an interesting analysis could also have been done with stage III and IV patients, since this group of people could benefit greatly from these findings. In fact, new guidelines now recommend the use of HER2-specific therapy for stage IV patients with positive markers, even for life if they do not show signs of progression. Additionally, we would like to discuss the value of adding the Ki-67 marker to the classification proposed by the authors, because several papers consider it an important prognostic factor.</description><subject>Biomarkers, Tumor</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>ErbB-2 protein</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Letter to the Editor</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1ksFu1DAQhiMEotvCA3BBlpBQD5vu2Ens5rhEC0WqRBUFrpaTOFuXxF5sBym3Pgg8AW_VJ8HbFGgRyAfbM9__yzOeKHqB4QQDsJXDkKV5DJjFKSUQT4-iBc5YEjOC2eNoAZiymJ4CPYgOnbsCgJxB_jQ6IDlhQPN8Ef0ozDBI7R0yGt1cfyuV-4xMhwZjveiVn_YXbVoZa7kVXn2VS7QpVxfl6mxTElRbKZxHjdCNtMiNtZ920iGlUYWXqCJLJHSLqgT5MTi6m-vvqJ7QhbDKSVSsb7OF2G6V0AZ9WqI3s18x-5XBqgoRv0QkFPksetKJ3snnd_tR9PHtpirO4vMP794X6_O4yXDi46Zuu6xNoBVAATpM06zOsoRS0ZGahCM9pTJpW5LjjmYipRl0DSSQUFxDnTbJUXQ8--6s-TJK5_mgXCP7XmhpRsdxzvI8tDXFAX31F3plRqvD624pxgJJ_lBb0UuudGe8Fc3elK-zJHxL4CBQJ_-gwmrloBqjZadC_IHg9T3BpRS9v3SmH70y2j0E8Qw21jhnZcd3Vg3CThwD308SnyeJhybz_STxKWhe3lU21oNsfyt-jU4AyAy4kNJbae-V_l_XnwtDz6M</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Pichilingue-Febres, Alejandra F.</creator><creator>Arias-Linares, Miguel A.</creator><creator>Araujo-Castillo, Roger V.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20180401</creationdate><title>Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017</title><author>Pichilingue-Febres, Alejandra F. ; Arias-Linares, Miguel A. ; Araujo-Castillo, Roger V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-cbdf5d30da0600f1645b55366af2b2b55686e3dd291f65a4650fc030361b0b4c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biomarkers, Tumor</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>ErbB-2 protein</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Letter to the Editor</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pichilingue-Febres, Alejandra F.</creatorcontrib><creatorcontrib>Arias-Linares, Miguel A.</creatorcontrib><creatorcontrib>Araujo-Castillo, Roger V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pichilingue-Febres, Alejandra F.</au><au>Arias-Linares, Miguel A.</au><au>Araujo-Castillo, Roger V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>168</volume><issue>2</issue><spage>577</spage><epage>578</epage><pages>577-578</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>We would like to express our opinion regarding a Parise and Caggiano paper recently published in your journal. We certainly believe this is a great contribution, since it found that node-negative HER2 (+) breast cancer patients have better survival contrary to the common knowledge. This finding could reflect the consequences of targeted therapies that are changing the natural history of the disease. However, we think that such an interesting analysis could also have been done with stage III and IV patients, since this group of people could benefit greatly from these findings. In fact, new guidelines now recommend the use of HER2-specific therapy for stage IV patients with positive markers, even for life if they do not show signs of progression. Additionally, we would like to discuss the value of adding the Ki-67 marker to the classification proposed by the authors, because several papers consider it an important prognostic factor.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29270699</pmid><doi>10.1007/s10549-017-4620-y</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2018-04, Vol.168 (2), p.577-578 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1979968041 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Biomarkers, Tumor Breast cancer Breast Neoplasms - metabolism Breast Neoplasms - mortality Breast Neoplasms - pathology ErbB-2 protein Female Health aspects Humans Letter to the Editor Medicine Medicine & Public Health Neoplasm Staging Oncology Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Tumors |
| title | Comments on “Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors” by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T00%3A29%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comments%20on%20%E2%80%9CRisk%20of%20mortality%20of%20node-negative,%20ER/PR/HER2%20breast%20cancer%20subtypes%20in%20T1,%20T2,%20and%20T3%20tumors%E2%80%9D%20by%20Parise%20CA%20and%20Caggiano%20V,%20Breast%20Cancer%20Res%20Treat,%202017&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Pichilingue-Febres,%20Alejandra%20F.&rft.date=2018-04-01&rft.volume=168&rft.issue=2&rft.spage=577&rft.epage=578&rft.pages=577-578&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-017-4620-y&rft_dat=%3Cgale_proqu%3EA530007770%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1979777992&rft_id=info:pmid/29270699&rft_galeid=A530007770&rfr_iscdi=true |